China National Pharmaceutical Foreign Trade To Build Investment Platform For Pharmaceutical Industry
This article was originally published in PharmAsia News
China National Pharmaceutical Foreign Trade Corporation, the wholly owned subsidiary of China National Pharmaceutical Group, has mapped out its medium- and long-term strategy that seeks strategic partnerships to establish an investment platform for the pharmaceutical industry. This will dovetail with the parent group's aim of consolidation and globalization of its pharmaceutical trade, technology and business. The trade corporation has collaborated with Otsuka Group, Johnson & Johnson, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, AstraZeneca and Kanebo and set up more than 10 joint ventures such as China Otsuka, Xian-Janssen, Shanghai Squibb, Suzhou Capsugel and Sino-Swed Pharmaceutical. It reported revenue of RMB 2 billion last year, with import and export amounting to RMB $300 million. (Click here for more - Chinese Language)
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.